 Pfizer Inc. PFE, 1.81 and Germany-based partner BioNTech SE BNTX, -3.39 said Thursday that their booster dose of the omicron BA.4BA.5-adapted bivalent COVID vaccine for 5-to-11 year olds was recommended for marketing authorization in the the European Union. The EU will review the recommendation from the European Medicines Agency EMA Committee for Medicinal Products for Human Use CHMP, and is expected to make a decision soon. 